Citation Impact
Citing Papers
Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice
2006
A Meta-Analysis of Cytokines in Major Depression
2009 Standout
Medication Augmentation after the Failure of SSRIs for Depression
2006 Standout
The effects of tryptophan depletion on mood and psychiatric symptoms
2001
A 9-Week Randomized Trial Comparing a Chronotherapeutic Intervention (Wake and Light Therapy) to Exercise in Major Depressive Disorder Patients Treated With Duloxetine
2012
Modulation of cardiac autonomic functions in patients with major depression treated with repetitive transcranial magnetic stimulation
2007
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
2006
Depression
2018 Standout
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies
2002
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
2009 Standout
Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major Depression
2005
Antidepressant Effects of High and Low Frequency Repetitive Transcranial Magnetic Stimulation to the Dorsolateral Prefrontal Cortex
2007
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
1995
Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation
2015 Standout
Glutamate receptor ion channels
2005 Standout
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
2010 Standout
Fluoxetine Combined with a Serotonin-1A Receptor Antagonist Reversed Reward Deficits Observed during Nicotine and Amphetamine Withdrawal in Rats
2001
Measuring and using light in the melanopsin age
2013 Standout
Efficacy and Tolerability of Reboxetine Compared with Citalopram
2006
Should We Expand the Toolbox of Psychiatric Treatment Methods to Include Repetitive Transcranial Magnetic Stimulation (rTMS)?
2010 Standout
Descending control of pain
2002 Standout
Glutamate uptake
2001 Standout
Decreased Hippocampal 5-HT2A Receptor Binding in Older Depressed Patients Using [18F]Altanserin Positron Emission Tomography
2004
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
2008
Efficacy of Transcranial Magnetic Stimulation Targets for Depression Is Related to Intrinsic Functional Connectivity with the Subgenual Cingulate
2012 Standout
Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis
2008
IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors
2006
When brain clocks lose track of time: cause or consequence of neuropsychiatric disorders
2011 StandoutNobel
Tryptophan depletion and its implications for psychiatry
2001
Network pharmacology: the next paradigm in drug discovery
2008 Standout
Psychedelics
2016 Standout
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
1998
Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients
2006
The interplay between the intestinal microbiota and the brain
2012 Standout
Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia
1998
Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression
2009
The pharmacology of putative early-onset antidepressant strategies
2003
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia
2000 StandoutNobel
Network interactions in schizophrenia — therapeutic implications
2000 StandoutNobel
Addiction Motivation Reformulated: An Affective Processing Model of Negative Reinforcement.
2004 Standout
Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline ‘Predictors’ and Longitudinal ‘Targets’
2012
Reciprocal regulation of the neural and innate immune systems
2011
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research
2009 Standout
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease
2016 Standout
Cytokines sing the blues: inflammation and the pathogenesis of depression
2005 Standout
Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia
2002 Standout
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Gut–brain axis: how the microbiome influences anxiety and depression
2013 Standout
Interferon-alpha–induced changes in tryptophan metabolism
2003
Current Issues in the Classification of Psychotic Major Depression
2007
N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology
2007 Standout
Host microbiota constantly control maturation and function of microglia in the CNS
2015 Standout
Treatment-emergent mania in unipolar and bipolar depression: focus on repetitive transcranial magnetic stimulation
2007
Impulsivity as a vulnerability marker for substance-use disorders: Review of findings from high-risk research, problem gamblers and genetic association studies
2008 Standout
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
2009 Standout
The HPA axis in major depression: classical theories and new developments
2008 Standout
Neurotransmitter interactions in schizophrenia—therapeutic implications
1999 StandoutNobel
Major Depressive Disorder
2008 Standout
A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression
2007
The gut microbiota — masters of host development and physiology
2013 Standout
Sleep deprivation in depression
2010
Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
2012 Standout
Interleukin-6, a mental cytokine
2011
Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications
1997 StandoutNobel
Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats
1996
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
The molecular neurobiology of depression
2008 StandoutNature
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
2001
The Intestinal Microbiota Affect Central Levels of Brain-Derived Neurotropic Factor and Behavior in Mice
2011 Standout
Impact of Depression and Antidepressant Treatment on Heart Rate Variability: A Review and Meta-Analysis
2010 Standout
The role of inflammation in depression: from evolutionary imperative to modern treatment target
2015 Standout
The Glutamate Hypothesis of Schizophrenia
1997
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Light therapy for non-seasonal depression
2004
N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade
2000
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy
2002
A glutamatergic deficiency model of schizophrenia
1999 StandoutNobel
Therapeutic use of sleep deprivation in depression
2002
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
1995
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
1997 Standout
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents
2000
Transcranial magnetic stimulation
2009
Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods
2019 Standout
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Host-Gut Microbiota Metabolic Interactions
2012 StandoutScience
Duloxetine versus other anti-depressive agents for depression
2012
Industry sponsorship and research outcome
2017 Standout
Hydrolysis and photolysis of paroxetine, a selective serotonin reuptake inhibitor, in aqueous solutions
2004
Excitatory Amino Acid Receptors in Schizophrenia
1993
Works of A. Lucca being referenced
Transcranial magnetic stimulation in treatment-resistant depressed patients: A double-blind, placebo-controlled trial
2005
Effects of Fluvoxamine Treatment on the in Vivo Binding of [F-18]FESP in Drug Naive Depressed Patients: A Pet Study
2000
Does rTMS Hasten the Response to Escitalopram, Sertraline, or Venlafaxine in Patients With Major Depressive Disorder? A Double-Blind, Randomized, Sham-Controlled Trial
2005
Simultaneous Determination of Human Plasma Levels of Four Selective Serotonin Reuptake Inhibitors by High-Performance Liquid Chromatography
2000
Neutral amino acid availability in two major psychiatric disorders
1995
Decrease in plasma phenylalanine and tyrosine after phenylalanine-tyrosine free amino acid solutions in man
1996
Effect of reboxetine augmentation in SSRI resistant patients
2000
Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance
2002
Plasma Tryptophan to Large Neutral Amino Acids Ratio and Therapeutic Response to a Selective Serotonin Uptake Inhibitor
1994
Plasma tryptophan levels and plasma tryptophan/ neutral amino acids ratio in patients with mood disorder, patients with obsessive-compulsive disorder, and normal subjects
1992
Serine and glycine metabolism in schizophrenic patients
1993
Amino acid patterns in schizophrenia: Some new findings
1990
Tryptophan depletion in obsessive-compulsive patients
1996
Sleep deprivation hastens the antidepressant action of fluoxetine
1997
Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction
2000
Faster Onset of Action of Fluvoxamine in Combination With Pindolol in the Treatment of Delusional Depression
1998
A STANDARDIZED TREATMENT OF DELUSIONAL DEPRESSION; PRELIMINARY RESULTS
1992